MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.
Revenue of MiNK Therapeutics, Inc. (INKT)
Revenue in 2023 (TTM): $
According to MiNK Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of MiNK Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-204,617 | $-22,716,487 | $-22,457,859 | $-22,457,859 |
| 2022 | $2.7 B | $-28,244,535,000 | $-30,827,529 | $-27,991,212 | $-24,779,823 |
| 2021 | $ | $-28,358,591,000 | $-28,058,711 | $-30,212,770 | $-23,114,009 |
| 2020 | $ | $-55,060 | $-13,742,935 | $-16,238,898 | $-15,678,517 |
| 2019 | $689.63 K | $689.63 K | $-22,204,498 | $-23,802,182 | $-25,914,285 |